Relative Bioavailability of Phase II and Phase III Formulations of AZD0530

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: AZD0530

Study type: Interventional

Funder types: Industry

Identifiers

NCT00771979

D8180C00033

Details and patient eligibility

About

The aim of the study is to compare how different formulations of AZD0530 are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Enrollment: 18 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Female subjects must be of Non- child-bearing potential
• Body mass index between 19 and 30 kg/m2 and weigh between 50-100 kg

Exclusion criteria

• Presence of any clinically significant illness
• Abnormal vital signs
• History of any conditions that may put the subject at risk by participating in the study
• Participation in another clinical study.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

1

Experimental group

Treatment:

Drug: AZD0530

Drug: AZD0530